Your browser doesn't support javascript.
loading
Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies.
Adachi, Yu; Tonouchi, Keisuke; Nithichanon, Arnone; Kuraoka, Masayuki; Watanabe, Akiko; Shinnakasu, Ryo; Asanuma, Hideki; Ainai, Akira; Ohmi, Yusuke; Yamamoto, Takuya; Ishii, Ken J; Hasegawa, Hideki; Takeyama, Haruko; Lertmemongkolchai, Ganjana; Kurosaki, Tomohiro; Ato, Manabu; Kelsoe, Garnett; Takahashi, Yoshimasa.
Afiliación
  • Adachi Y; Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo, 162-8640, Japan.
  • Tonouchi K; Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo, 162-8640, Japan.
  • Nithichanon A; Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsucho, Shinjuku, Tokyo, 162-8480, Japan.
  • Kuraoka M; Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo, 162-8640, Japan.
  • Watanabe A; Center for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, 123 Mittraphap Road, Khon Kaen, 40002, Thailand.
  • Shinnakasu R; Department of Immunology, Duke University, Durham, NC, 27710, USA.
  • Asanuma H; Department of Immunology, Duke University, Durham, NC, 27710, USA.
  • Ainai A; Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center and Graduate School of Frontier Biosciences, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
  • Ohmi Y; Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo, 208-0011, Japan.
  • Yamamoto T; Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo, 162-8640, Japan.
  • Ishii KJ; Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo, 162-8640, Japan.
  • Hasegawa H; Department of Clinical Engineering, Chubu University College of Life and Health Sciences, 1200 Matsumoto, Kasugai, 487-8501, Aichi, Japan.
  • Takeyama H; Laboratory of Immunosenescence, Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saitoasagi, Ibaraki, Osaka, 567-0085, Japan.
  • Lertmemongkolchai G; Center for Vaccine and Adjuvant Research, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saitoasagi, Ibaraki, Osaka, 567-0085, Japan.
  • Kurosaki T; Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shiroganedai, Minato, Tokyo, 108-8639, Japan.
  • Ato M; Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo, 208-0011, Japan.
  • Kelsoe G; Department of Pathology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo, 162-8640, Japan.
  • Takahashi Y; Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsucho, Shinjuku, Tokyo, 162-8480, Japan.
Nat Commun ; 10(1): 3883, 2019 08 28.
Article en En | MEDLINE | ID: mdl-31462639
ABSTRACT
Germinal center (GC) B cells at viral replication sites acquire specificity to poorly immunogenic but conserved influenza hemagglutinin (HA) epitopes. Here, high-throughput epitope mapping of local GC B cells is used to identify conserved HA epitope selecting cross-reactive antibodies that mediate heterosubtypic protection. A distinct feature of this epitope is an occlusion in the naive trimeric HA structure that is exposed in the post-fusion HA structure to occur under low pH conditions during viral replication. Importantly, systemic immunization by the post-fusion HA antigen results in GC B cells targeting the occluded epitope, and induces a class of protective antibodies that have cross-group specificity and afford protection independent of virus neutralization activity. Furthermore, this class of broadly protective antibodies develops at late time points and persists. Our results identify a class of cross-protective antibodies that are selected at the viral replication site, and provide insights into vaccine strategies using the occluded epitope.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus de la Influenza A / Linfocitos B / Glicoproteínas Hemaglutininas del Virus de la Influenza / Anticuerpos Antivirales / Epítopos Límite: Animals / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus de la Influenza A / Linfocitos B / Glicoproteínas Hemaglutininas del Virus de la Influenza / Anticuerpos Antivirales / Epítopos Límite: Animals / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2019 Tipo del documento: Article País de afiliación: Japón